In recent years, the therapeutic landscape of myeloid malignancies has been completely
revolutionized by the introduction of several new drugs, targeting molecular alterations or …

In recent decades, millions of patients with cancer have been cured by chemotherapy alone.
By 'cure', we mean that patients with cancers that would be fatal if left untreated receive a …

Deep single-cell multi-omic profiling offers a promising approach to understand and
overcome drug resistance in relapsed or refractory (rr) acute myeloid leukemia (AML). Here …

Core binding factor acute myeloid leukemia (CBF-AML) features the recurrent chromosomal
rearrangements t (8; 21)(q22; 22) and inv (16)(p13. 1q22)/t (16; 16)(p13. 1; q22), which …

Purpose: Leukemic stem cells (LSC) are responsible for leukemia initiation, relapse, and
therapeutic resistance. Therefore, the development of novel therapeutic approaches …

Purpose: We investigated whether homoharringtonine (HHT) added to venetoclax plus
azacitidine (VA) could improve outcomes and counteract the negative effects of genetic …

NRAS and KRAS activating point mutations are present in 10–30% of myeloid malignancies
and are often associated with a proliferative phenotype. RAS mutations harbor allele …

Engineering immune cells to treat hematological malignancies has been a major focus of
research since the first resounding successes of CAR-T-cell therapies in B-ALL. Several …

Acute myeloid leukemia (AML) is a lethal hematologic malignancy. Chemotherapy
resistance results in a dismal survival rate of 1–2 years in older adults with AML. Therefore …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive subtype of
myeloid malignancy characterized by skin, lymph node and central nervous system (CNS) …